Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Sells $15,672.25 in Stock

Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Andrew Spaventa sold 695 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $22.55, for a total transaction of $15,672.25. Following the sale, the chief executive officer now owns 1,537 shares of the company’s stock, valued at $34,659.35. This represents a 31.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew Spaventa also recently made the following trade(s):

• On Sunday, September 15th, Andrew Spaventa sold 175 shares of Singular Genomics Systems stock. The stock was sold at an average price of $12.38, for a total transaction of $2,166.50.

Singular Genomics Systems Stock Performance

Shares of NASDAQ:OMIC opened at $22.75 on Friday. Singular Genomics Systems, Inc. has a 1 year low of $5.34 and a 1 year high of $23.41. The company has a debt-to-equity ratio of 0.04, a quick ratio of 8.04 and a current ratio of 7.37. The stock’s 50-day moving average is $15.32 and its 200 day moving average is $11.33.

Singular Genomics Systems (NASDAQ:OMIC) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($6.72) EPS for the quarter, topping analysts’ consensus estimates of ($8.05) by $1.33. Singular Genomics Systems had a negative return on equity of 57.87% and a negative net margin of 3,237.89%. The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $0.74 million.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.